Senate passes a “right to try” bill; Harm to patients comes next

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Patients for whom there are no existing treatments watch with desperation as a potentially helpful new drug spends years working its way from a lab bench, through clinical trials, and finally to the FDA, where reviewers consider it for approval.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Kelly McBride Folkers
Research associate, Division of Medical Ethics, NYU School of Medicine
Lisa Kearns
Senior research associate, Division of Medical Ethics, NYU School of Medicine
Alison Bateman-House
Assistant professor in the Division, co-chair of NYU's Working Group on Compassionate Use and Pre-Approval Access.
Table of Contents

YOU MAY BE INTERESTED IN

“Backwater to Blockbuster,” the first de novo book published by the Cancer History Project, traces the evolution of St. Jude Children’s Research Hospital to its current status of a powerhouse of research in pediatric cancer.

The U.S. Department of Justice issued a letter alleging that Yale Medical School of violating anti-discrimination laws and instititing policies that disadvantaged white and Asian applicants while favoring Black and Hispanic applicants.  The DOJ investigation, which was launched a year ago, reviewed the school’s admission policies for the class of 2023, 2024, and 2025, the...

Kelly McBride Folkers
Research associate, Division of Medical Ethics, NYU School of Medicine
Lisa Kearns
Senior research associate, Division of Medical Ethics, NYU School of Medicine
Alison Bateman-House
Assistant professor in the Division, co-chair of NYU's Working Group on Compassionate Use and Pre-Approval Access.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login